Live
FierceBiotechAltai Capital angles for OraSure board seats and a saleFierceBiotechXaira exec divulges R&D focus, how $1B fundraise fuels AI-driven hunt for what the 'industry is hungriest for'Cytiva (Google News)Class action accuses Danaher of turning DEI into hiring quotas - hcamag.comEndpoints NewsCMS innovation center to expand team focused on drug pricesEndpoints NewsAldeyra dry eye drug gets third rejection from FDA, triggering stock slide10x Genomics Blog10x Genomics (NASDAQ:TXG) Stock Price Up 6.9% - Time to Buy? - MarketBeatEndpoints NewsDrugmakers consider licensing deal tweaks to soften MFN impactThermo FisherHow Niton XRF Technology is Transforming Precious Metals Analysis - AZoMEndpoints NewsKaren Weintraub and Kevin Miller to join Endpoints News as editorsEndpoints NewsThe latest in Epic's fight over patient health dataFierceBiotechAlcon, Lensar drop $356M acquisition deal after black eye from FTCFierceBiotechFDA rejects Aldeyra dry eye disease drug for 3rd time, citing inconsistent study findings
10x Genomics Blog Mar 17, 2026

10x Genomics (NASDAQ:TXG) Stock Price Up 6.9% - Time to Buy? - MarketBeat

10x Genomics (NASDAQ:TXG) Stock Price Up 6.9% - Time to Buy? - MarketBeat

Original
Body unavailable. Use the original source.

Directory

59 All